Ketorolac, nimesulide, nabumetone and nefopam
Analgesic and anti-inflammatory medicaments (ketorolac, nimesulide, nabumetone, nefopam)
HSN 3004 90 67 (Ketorolac, nimesulide, nabumetone and nefopam) is subject to Central Drugs Standard Control Organisation (CDSCO) drug registration and import licensing under the Drugs and Cosmetics Act, 1940. Mandatory e-Sanchit documentation — including a registration certificate, import licence, certificate of analysis, batch release certificate, and consignment label — must be uploaded before out-of-charge at the bill of entry. The Directorate General of Foreign Trade (DGFT) administers the ITC (HS) import policy overlay applicable to this tariff line.
- Registration certificate from CDSCO
- Import licence from CDSCO
- Certificate of Analysis from manufacturer
Procedural directions for customs clearance are issued by: Directorate General of Foreign Trade.
- 1Obtain a valid drug registration certificate and an import licence for drugs from CDSCO covering each formulation to be imported. Both documents must be uploaded in e-Sanchit under document codes 101dc1 (registration certificate) and 9111dc (import licence for drugs) before filing the bill of entry.Drugs and Cosmetics Act, 1940 · document codes 101dc1 and 9111dc
- 2Upload in e-Sanchit the Certificate of Analysis for drugs (document code 0010dc), the Batch Release Certificate (document code 0030dc), and the Label of Consignment (document code 0110dc) before the proper officer grants out-of-charge. Absence of any one of these codes on a PGA-facilitated bill triggers detention pending manual verification.e-Sanchit mandatory document requirement · document codes 0010dc, 0030dc, 0110dc
The most common error on this tariff line is uploading the registration certificate without confirming that the specific formulation strength and dosage form are covered by the registration — CDSCO registrations are formulation-specific, and a certificate covering a 10 mg tablet does not authorise import of a 30 mg injection. A mismatch between the registered formulation and the shipped product results in consignment detention, demurrage, and potential confiscation under the Drugs and Cosmetics Act, 1940.